JHL Biotech
26 articles about JHL Biotech
-
A closer look at legal action against executives from the company formerly known as JHL Biotech who recruited scientists from Genentech to steal trade secrets related to several cancer drugs.
-
Two former executives of JHL Biotech were sentenced to a year and one day each in prison after being found guilty of conspiracy and fraud.
-
Chin, 57, and Humad, 36, along with the company, were indicted on charges of paying surgeons to use their spinal implants in surgeries.
-
Genentech’s Hemlibra showed no new safety signals and continued to deliver consistent bleeding control in the final analysis of a long-term, late-stage hemophilia A study.
-
The two were charged with conspiracy to commit trade secret theft and wire fraud, international money laundering and obstruction of justice.
-
First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar
5/18/2020
JHL Biotech, Inc. today announced that the first group of subjects has been randomized and dosed last week in the company's Australian Phase I Clinical Trial of JHL1266 in healthy subjects. The Three-A
-
Nearly one year after charges were filed against former Genentech employees accused of stealing trade secrets to benefit JHL Biotech, the two companies have come to an agreement over the ill-gotten intellectual property – destruction.
-
Four former Genentech employees have been indicted by a federal grand jury for the alleged theft of company trade secrets in order to help a company set up in Taiwan develop drugs similar to those made by the Roche subsidiary.
-
More and more pharma companies follow the trend of planning initial public offerings on the Hong Kong Stock Exchange. Another trend following this path is the number of prominent investment bankers who have left their firms for biotech companies in the former British colony.
-
JHL Shareholders Approve Voluntary De-Listing from Taiwan Exchange
2/5/2018
The shareholders of JHL Biotech voted to approve the company's voluntary delisting from the Taiwan stock exchange.
-
JHL Biotech Proposes Voluntary Delisting from Taiwan Exchange
12/22/2017
The biosimilar company, which has a $419M market capitalization, operates in Taiwan and Wuhan, China.
-
China FDA Accepts JHL Biotech's First Clinical Trial Application
4/5/2017
-
JHL Biotech Doses First Patient In JHL1101 Phase I European Trial
3/29/2017
-
Week In Review: JHL Biotech Signs $257 Million Biosimilar Deal With Sanofi
12/12/2016
-
Sanofi And JHL Biotech Announce Strategic Biologics Alliance In China
12/5/2016
-
Taiwan-Based JHL Biotech Selects PaizaBio To Provide Fill-And-Finish CMO Services For Groundbreaking Therapies
5/17/2016
-
JHL Biotech Opens Innovative Biosimilars Manufacturing Facility In China
5/10/2016
-
JHL Biotech And Affinita Biotech Agree To Partner In The Development And Manufacturing Of Oncology Monoclonal Antibodies
3/1/2016
-
JHL Biotech Announces Mechanical Completion Of Its Wuhan Biopharmaceutical Manufacturing Facility
2/25/2016
-
JHL Biotech Receives Approval From European Authorities To Begin Biosimilar Clinical Trial
2/15/2016